Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction

Clinical Colorectal Cancer

Volumn 10, Issue 1, 2011, Pages E6-

  Roderburg, Christoph ^a   Do O, Nicole ^a   Fuchs, Roland ^a   Bubenzer, Jhenee ^a   Spannbauer, Michael ^a   Luedde, Tom ^a   Trautwein, Christian ^a   Tischendorf, Jens J W ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Liver dysfunction; Oxaliplatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; BILIRUBIN GLUCURONIDE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

ABDOMINAL PAIN; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CASE REPORT; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; JAUNDICE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHYSICAL PERFORMANCE; PROTEIN BLOOD LEVEL; RECTUM CARCINOMA; SIGMOID CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT REDUCTION; COLORECTAL TUMOR; DISEASE COURSE; LIVER TUMOR; METASTASIS; PATHOLOGY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIRUBIN; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; ORGANOPLATINUM COMPOUNDS;

EID: 80053451569     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.3816/CCC.2011.n.011     Document Type: Article

References (16)

1. B Glimelius, K Hoffman, W Graf et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer Cancer 73 1994 556 562 (Pubitemid 24046593)
2. B Gruenberger, W Scheithauer, R Punzengruber et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases BMC Cancer 8 2008 120
3. S Jonas, A Thelen, C Benckert et al. Extended resections of liver metastases from colorectal cancer World J Surg 31 2007 511 521 (Pubitemid 46356071)
4. A de Gramont, A Figer, M Seymour et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947 (Pubitemid 30644117)
5. B Glimelius, L Pahlman Cytostatic drug therapy in disseminated colorectal cancer Scand J Gastroenterol Suppl 149 1988 181 189
6. RM Goldberg, DJ Sargent, RF Morton et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30 (Pubitemid 41095110)
7. S Wilop, R Dada, O Galm et al. Cisplatin as single-agent chemotherapy in patients with liver dysfunction due to metastases Onkologie 32 2009 400 404
8. GF Fleming, RL Schilsky, LP Schumm et al. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction Ann Oncol 14 2003 1142 1147 (Pubitemid 36950181)
9. E Raymond, V Boige, S Faivre et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction J Clin Oncol 20 2002 4303 4312 (Pubitemid 35266290)
10. TW Synold, CH Takimoto, JH Doroshow et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study Clin Cancer Res 13 2007 3660 3666 (Pubitemid 46955130)
11. RK Ramanathan, ML Rothenberg, A de Gramont et al. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies Ann Oncol 21 2010 754 758
12. JM Extra, M Marty, S Brienza et al. Pharmacokinetics and safety profile of oxaliplatin Semin Oncol 25 1998 13 22 (Pubitemid 28248697)
13. SJ Hwang, JW Park, SD Lee et al. Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction Korean J Intern Med 21 2006 252 255
14. M Baur, A Drescher, M Gneist et al. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction Cancer Chemother Pharmacol 61 2008 97 104 (Pubitemid 47512631)
15. T Grenader, A Goldberg, A Gabizon Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel Anticancer Drugs 20 2009 845 847
16. MG Fakih 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction Oncology 67 2004 222 224 (Pubitemid 39551705)